Latest Breaking News On - Primon lara jr - Page 1 : comparemela.com

Bone Biomarkers Predict Survival in Hormone-Sensitive Prostate Cancer

The findings can be used in patient counseling. Research confirms the clinical benefit of assessing bone biomarkers in hormone-sensitive prostate cancer.

United statesUniversity of california davisPrimon lara jrUniversity of california davis comprehensive cancer centerCalifornia davis comprehensive cancer center

Everolimus after surgery may benefit patients with very-high-risk clear cell renal cell carcinoma

A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo after surgery.

United statesSan antonioMaxwell mengIgor puzanovPrimon lara jrAjjais alvaJosephi clarkNeeraj agarwalTonik choueiriDanielle ellisNaomib haasUlkan vaishampayanCatherinem tangenElisabethi heathBrianm shuchChristopherw ryan

High-Risk Renal Cell Carcinoma Patients Benefit from Everolimus

High-Risk Renal Cell Carcinoma Patients Benefit from Everolimus
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesNaomib haasTonik choueiriMarkn steinIanm thompsonUlkan vaishampayanSumantak palBrianm shuchIgor puzanovAjjais alvaChristopherw ryanCatherinem tangenJosephi clarkMaxwell mengNeeraj agarwal

Highest risk patients with clear-cell renal cell carcinoma benefit from adjuvant everolimus: Clinical trial

Highest risk patients with clear-cell renal cell carcinoma benefit from adjuvant everolimus: Clinical trial
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United statesPrimon lara jrChristopherw ryanOregon healthUc davis comprehensive cancer centerCancer research networkUniversity of california davis school medicineScience university knight cancer instituteDrug administrationEuropean society of medical oncologyEuropean societyMedical oncologyCalifornia davis schoolComprehensive cancer center

Cabozantinib most effective treatment for metastatic papillary kidney cancer

E-Mail IMAGE: Sumanta Pal, MD, a SWOG Cancer Research Network researcher and City of Hope physician, led a study that sets a new standard of care for metastatic papillary kidney cancer view more Credit: City of Hope In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer - findings expected to change medical practice. These findings will be presented at ASCO s virtual 2021 Genitourinary Cancers Symposium on Feb. 13, 2021 at 1 p.m. ET. The findings will be simultaneously published in

United statesWayne state universityJohn wrightScott coleLos angelesCatherine tangenIanm thompson jrNaomi balzer haasDanielj georgeGeorga bjarnasonMark steinUlka vaishampayanMaria tretiakovaDaniel yc hengBrian shuchAdebowale adeniran